GlaxoSmithKline forges Russian vaccines alliance
pharmafile | November 30, 2010 | News story | Manufacturing and Production | GSK, GlaxoSmithKline, JSC Binnopharm, cervical cancer vaccine, pharma manufacturing, pneumococcal vaccine, rotavirus vaccine, vaccines
GlaxoSmithKline has announced an alliance with JSC Binnopharm focusing on the secondary manufacture of a number of the pharmaceutical giant’s vaccine products in Russia.
The agreement will see GSK supply bulk vaccine and provide technology and expertise to Binnopharm, to enable the Russian company to carry out filling and packaging of a number of GSK vaccines.
Moscow-based Binnopharm will also be responsible for gaining approval for a supply of GlaxoSmithKline cervical cancer, rotavirus and pneumococcal vaccines – under Binnopharm’s trademark – for the Russian public market.
Binnopharm is one of the largest biopharmaceutical operations in Russia with manufacturing facilities covering more than 32,000 sq.m.
Local manufacture of these vaccines will help Russia modernise its national immunisation calendar, adding additional vaccinations against highly prevalent infections including human papillomavirus (HPV), rotavirus and Streptococcus pneumoniae, said GSK.
GSK will book sales of the bulk vaccine supplied to Binnopharm through this alliance, although further financial details of the agreement have not been disclosed.
The deal was welcomed by Vince Cable, the UK Secretary of State for Business, Innovation and Skills, who said it is “a very positive outcome and one which emphasises the strong pharmaceutical links that the UK shares with Russia”.
Other drugmakers have forged ties with Russian companies to secure access to the country’s fast-growing vaccines market, notably Abbott Laboratories which has an ongoing joint venture with Petrovax Pharm, inherited as part of its purchase of Solvay’s pharmaceutical unit earlier this year.
The Russian government said last year it would give more benefits to local producers as it moves to improve health care and modernise the pharmaceutical sector, prompting many international drug makers to explore the idea of establishing local manufacturing there, according to a report in the Moscow Times.
Phil Taylor
Related Content
GSK shares results from phase 3 trial for gonorrhoea treatment
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …
GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment
GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase …
